Rapport Therapeutics Net Income

Rapport Therapeutics (RAPP) currently reports a net income of $-140M as of June 2026. That compares with $-88M in the prior-year period — down 55.3% year over year. That is below the sector sector average of $96M. Use the charts on this page to explore Rapport Therapeutics's net income history and peer comparisons.

Rapport Therapeutics's net income decreased from $-88M to $-140M — a 55.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Rapport Therapeutics's net income of $-140M is lower than the its sector sector average of $96M. That is roughly 242.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Rapport Therapeutics reported $-140M in net income as of June 2026. That compares with $-88M in the prior-year period — down 55.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-140M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $96M. From there, open related valuation or income-statement pages for Rapport Therapeutics, and consider following RAPP for alerts when major investors trade the stock.